IL214745A0 - Treatment of insulin-resistant disorders - Google Patents

Treatment of insulin-resistant disorders

Info

Publication number: IL214745A0
Authority: IL; Israel
Prior art keywords: insulin; treatment; resistant disorders; disorders; resistant
Prior art date: 2009-04-01

Application number

IL214745A

Other languages

English (en)

Original Assignee

Genentech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-04-01

Filing date

2011-08-18

Publication date

2011-11-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42229822&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL214745(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-08-18 Application filed by Genentech Inc filed Critical Genentech Inc

2011-11-30 Publication of IL214745A0 publication Critical patent/IL214745A0/en

Links

NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title 2
102000004877 Insulin Human genes 0.000 title 1
108090001061 Insulin Proteins 0.000 title 1
229940125396 insulin Drugs 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Immunology (AREA)
Endocrinology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Obesity (AREA)
Hematology (AREA)
Mycology (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Reproductive Health (AREA)
Child & Adolescent Psychology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Emergency Medicine (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

IL214745A 2009-04-01 2011-08-18 Treatment of insulin-resistant disorders IL214745A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US16567709P	2009-04-01	2009-04-01
PCT/US2010/029280 WO2010114859A1 (en)	2009-04-01	2010-03-30	Treatment of insulin-resistant disorders

Publications (1)

Publication Number	Publication Date
IL214745A0 true IL214745A0 (en)	2011-11-30

Family

ID=42229822

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL214745A IL214745A0 (en)	2009-04-01	2011-08-18	Treatment of insulin-resistant disorders

Country Status (24)

Country	Link
US (1)	US20100266595A1 (zh)
EP (1)	EP2413967A1 (zh)
JP (1)	JP5795306B2 (zh)
KR (1)	KR101766927B1 (zh)
CN (1)	CN102448493B (zh)
AR (1)	AR075998A1 (zh)
AU (1)	AU2010232692C1 (zh)
BR (1)	BRPI1011535A2 (zh)
CA (1)	CA2752908A1 (zh)
CL (1)	CL2011002416A1 (zh)
CO (1)	CO6410313A2 (zh)
CR (1)	CR20110552A (zh)
EC (1)	ECSP11011429A (zh)
IL (1)	IL214745A0 (zh)
MA (1)	MA33248B1 (zh)
MX (1)	MX347978B (zh)
NZ (1)	NZ595005A (zh)
PE (1)	PE20120628A1 (zh)
RU (1)	RU2537142C2 (zh)
SG (1)	SG174891A1 (zh)
TW (1)	TWI474833B (zh)
UA (1)	UA105384C2 (zh)
WO (1)	WO2010114859A1 (zh)
ZA (1)	ZA201106076B (zh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20050118232A1 (en) *	2002-02-12	2005-06-02	Elvira Pistolesi	N-acyl-phosphatidyl-ethanolamines and/or mixtures of n-acyl-ethanolamines with phosphatidic acids or lysophosphatidic acids
KR20110025649A (ko)	2008-05-05	2011-03-10	노비뮨 에스 에이	항-ｉｌ-１７ａ／ｉｌ-１７ｆ 교차-반응성 항체 및 그의 사용 방법
US8790642B2 (en)	2008-08-29	2014-07-29	Genentech, Inc.	Cross-reactive and bispecific anti-IL-17A/F antibodies
EP3214442A1 (en)	2010-10-25	2017-09-06	F. Hoffmann-La Roche AG	Treatment of gastrointestinal inflammation and psoriasis and asthmainflammation and psoriasis a
US9117641B2 (en)	2012-10-29	2015-08-25	Perkinelmer Health Sciences, Inc.	Direct sample analysis device adapters and methods of using them
TWI780236B (zh) *	2013-02-04	2022-10-11	法商賽諾菲公司	胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
PT2950780T (pt) *	2013-02-04	2020-07-07	Sanofi Sa	Formulações farmacêuticas estabilizadas de análogos de insulina e/ou derivados de insulina
WO2015104314A1 (en)	2014-01-09	2015-07-16	Sanofi	Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
WO2018161340A1 (en) *	2017-03-10	2018-09-13	X-Kang United Biopharmaceutical Science & Technology Co., Ltd.	Monoclonal antibody against both il-17a and il-17f and use of the same

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
US4179337A (en)	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
JPS6023084B2 (ja)	1979-07-11	1985-06-05	味の素株式会社	代用血液
US4485045A (en)	1981-07-06	1984-11-27	Research Corporation	Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en)	1981-10-30	1987-02-03	Nippon Chemiphar Company, Ltd.	Plasminogen activator derivatives
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4544545A (en)	1983-06-20	1985-10-01	Trustees University Of Massachusetts	Liposomes containing modified cholesterol for organ targeting
US4496689A (en)	1983-12-27	1985-01-29	Miles Laboratories, Inc.	Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (de)	1985-06-19	1990-12-20	Ajinomoto Kk	Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4676980A (en)	1985-09-23	1987-06-30	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Target specific cross-linked heteroantibodies
US4783469A (en)	1986-03-07	1988-11-08	Meier Albert H	Method of inhibiting body fat stores
US4791192A (en)	1986-06-26	1988-12-13	Takeda Chemical Industries, Ltd.	Chemically modified protein with polyethyleneglycol
IL85035A0 (en)	1987-01-08	1988-06-30	Int Genetic Eng	Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5266561A (en)	1988-01-11	1993-11-30	Amylin Pharmaceuticals, Inc.	Treatment of type 2 diabetes mellitus
EP0425482B1 (en)	1988-07-20	1993-08-18	Novo Nordisk A/S	Human insulin analogs and preparations containing them
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
US5175384A (en)	1988-12-05	1992-12-29	Genpharm International	Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5514646A (en)	1989-02-09	1996-05-07	Chance; Ronald E.	Insulin analogs modified at position 29 of the B chain
US5116964A (en)	1989-02-23	1992-05-26	Genentech, Inc.	Hybrid immunoglobulins
DE3920358A1 (de)	1989-06-22	1991-01-17	Behringwerke Ag	Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
CA2062795A1 (en)	1989-06-29	1990-12-30	Michael W. Fanger	Bispecific reagents for aids therapy
US5013556A (en)	1989-10-20	1991-05-07	Liposome Technology, Inc.	Liposomes with enhanced circulation time
DK0710719T3 (da)	1990-01-12	2007-07-09	Amgen Fremont Inc	Frembringelse af xenogene antistoffer
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
EP0814159B1 (en)	1990-08-29	2005-07-27	GenPharm International, Inc.	Transgenic mice capable of producing heterologous antibodies
JPH06507398A (ja)	1991-05-14	1994-08-25	リプリジェン　コーポレーション	Ｈｉｖ感染治療のための異種複合抗体
CA2103059C (en)	1991-06-14	2005-03-22	Paul J. Carter	Method for making humanized antibodies
WO1993008829A1 (en)	1991-11-04	1993-05-13	The Regents Of The University Of California	Compositions that mediate killing of hiv-infected cells
WO1993011161A1 (en)	1991-11-25	1993-06-10	Enzon, Inc.	Multivalent antigen-binding proteins
EP0625200B1 (en)	1992-02-06	2005-05-11	Chiron Corporation	Biosynthetic binding protein for cancer marker
EP0656064B1 (en)	1992-08-17	1997-03-05	Genentech, Inc.	Bispecific immunoadhesins
EP0671936A1 (en)	1992-10-15	1995-09-20	Dana-Farber Cancer Institute, Inc.	TREATMENT OF INSULIN RESISTANCE IN OBESITY LINKED TYPE II DIABETES USING ANTAGONISTS TO TNF-$g(a) FUNCTION
US5527307A (en)	1994-04-01	1996-06-18	Minimed Inc.	Implantable medication infusion pump with discharge side port
US5534615A (en)	1994-04-25	1996-07-09	Genentech, Inc.	Cardiac hypertrophy factor and uses therefor
US5569186A (en)	1994-04-25	1996-10-29	Minimed Inc.	Closed loop infusion pump system with removable glucose sensor
US6214388B1 (en)	1994-11-09	2001-04-10	The Regents Of The University Of California	Immunoliposomes that optimize internalization into target cells
US5939269A (en)	1994-12-28	1999-08-17	The Regents Of The University Of California	Antagonists to insulin receptor tyrosine kinase inhibitor
US5637095A (en)	1995-01-13	1997-06-10	Minimed Inc.	Medication infusion pump with flexible drive plunger
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
US5641870A (en)	1995-04-20	1997-06-24	Genentech, Inc.	Low pH hydrophobic interaction chromatography for antibody purification
ATE390933T1 (de)	1995-04-27	2008-04-15	Amgen Fremont Inc	Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
EP0823941A4 (en)	1995-04-28	2001-09-19	Abgenix Inc	HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
JPH11510170A (ja)	1995-07-27	1999-09-07	ジェネンテックインコーポレーテッド	タンパク質の処方
EP0766966A3 (en)	1995-09-08	2001-02-28	Eli Lilly And Company	Method of treating insulin resistance
DE19544393A1 (de)	1995-11-15	1997-05-22	Hoechst Schering Agrevo Gmbh	Synergistische herbizide Mischungen
IL120443A (en)	1996-03-18	2000-07-16	Sankyo Co	Use of an insulin sensitizer for the manufacture of a medicament for the treatment or prophylaxis of pancreatitis
EP0942968B1 (en)	1996-12-03	2008-02-27	Amgen Fremont Inc.	Fully human antibodies that bind EGFR
US20020177188A1 (en)	1998-05-15	2002-11-28	Genentech, Inc.	IL-17 homologous polypeptides and therapeutic uses thereof
US6040292A (en)	1999-06-04	2000-03-21	Celtrix Pharmaceuticals, Inc.	Methods for treating diabetes
US6187333B1 (en)	1999-09-20	2001-02-13	Diabex, Inc.	Method for treating, controlling, and preventing diabetes mellitus
ATE444361T1 (de)	1999-12-23	2009-10-15	Genentech Inc	Il-17 und il-17r homologe polypeptide und deren therapeutische verwendungen
US20070160576A1 (en) *	2001-06-05	2007-07-12	Genentech, Inc.	IL-17A/F heterologous polypeptides and therapeutic uses thereof
ES2304072B1 (es) *	2001-10-15	2009-07-07	Genentech, Inc.	Tratamiento y diagnostico de trastornos resistentes a la insulina.
EP1513879B1 (en)	2002-06-03	2018-08-22	Genentech, Inc.	Synthetic antibody phage libraries
ATE427754T1 (de) *	2004-09-21	2009-04-15	Merck Serono Sa	Verwendung von il-17f zur behandlung und/oder pravention von neurologischen erkrankungen
WO2007027761A2 (en) *	2005-09-01	2007-03-08	Schering Corporation	Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease
US7910703B2 (en) *	2006-03-10	2011-03-22	Zymogenetics, Inc.	Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
US7790163B2 (en) *	2006-03-10	2010-09-07	Zymogenetics, Inc.	Antibodies that bind both IL-17A and IL-17F and methods of using the same
TW200902064A (en) *	2007-03-28	2009-01-16	Wyeth Corp	Methods and compositions for modulating IL-17F/IL-17A biological activity
CA2682889C (en) *	2007-04-27	2016-04-05	Zymogenetics, Inc.	Antibodies that bind both il-17a and il-17f and methods of using the same
WO2008134659A2 (en) *	2007-04-27	2008-11-06	Zymogenetics, Inc.	Antagonists to il-17a, il-17f, and il-23p19 and methods of use
ES2614735T3 (es) *	2007-07-23	2017-06-01	Janssen Biotech, Inc.	Métodos y composiciones para tratar los trastornos relacionados con fibrosis usando antagonistas de la IL-17
US20110002994A1 (en) *	2007-10-02	2011-01-06	Institut National De La Recherche Scientifique	Method of regulating the th17 pathway and its associated metabolic impact

2010
- 2010-03-30 CA CA2752908A patent/CA2752908A1/en not_active Abandoned
- 2010-03-30 CN CN201080023924.3A patent/CN102448493B/zh active Active
- 2010-03-30 MA MA34316A patent/MA33248B1/fr unknown
- 2010-03-30 WO PCT/US2010/029280 patent/WO2010114859A1/en active Application Filing
- 2010-03-30 EP EP10712243A patent/EP2413967A1/en not_active Withdrawn
- 2010-03-30 SG SG2011068293A patent/SG174891A1/en unknown
- 2010-03-30 PE PE2011001691A patent/PE20120628A1/es not_active Application Discontinuation
- 2010-03-30 MX MX2011010273A patent/MX347978B/es active IP Right Grant
- 2010-03-30 AR ARP100101033A patent/AR075998A1/es not_active Application Discontinuation
- 2010-03-30 UA UAA201112634A patent/UA105384C2/ru unknown
- 2010-03-30 JP JP2012503632A patent/JP5795306B2/ja active Active
- 2010-03-30 KR KR1020117025865A patent/KR101766927B1/ko active IP Right Grant
- 2010-03-30 RU RU2011144122/15A patent/RU2537142C2/ru not_active IP Right Cessation
- 2010-03-30 TW TW099109698A patent/TWI474833B/zh not_active IP Right Cessation
- 2010-03-30 BR BRPI1011535A patent/BRPI1011535A2/pt not_active IP Right Cessation
- 2010-03-30 NZ NZ595005A patent/NZ595005A/en not_active IP Right Cessation
- 2010-03-30 AU AU2010232692A patent/AU2010232692C1/en not_active Ceased
- 2010-03-30 US US12/749,876 patent/US20100266595A1/en not_active Abandoned
2011
- 2011-08-18 ZA ZA2011/06076A patent/ZA201106076B/en unknown
- 2011-08-18 IL IL214745A patent/IL214745A0/en unknown
- 2011-08-24 CO CO11108185A patent/CO6410313A2/es not_active Application Discontinuation
- 2011-09-30 CL CL2011002416A patent/CL2011002416A1/es unknown
- 2011-10-19 CR CR20110552A patent/CR20110552A/es unknown
- 2011-11-01 EC EC2011011429A patent/ECSP11011429A/es unknown

Also Published As

Publication number	Publication date
CR20110552A (es)	2011-12-07
US20100266595A1 (en)	2010-10-21
PE20120628A1 (es)	2012-05-26
JP2012522788A (ja)	2012-09-27
CL2011002416A1 (es)	2012-04-20
RU2011144122A (ru)	2013-05-10
CN102448493B (zh)	2014-04-30
CO6410313A2 (es)	2012-03-30
CA2752908A1 (en)	2010-10-07
WO2010114859A1 (en)	2010-10-07
ECSP11011429A (es)	2011-12-30
TWI474833B (zh)	2015-03-01
KR101766927B1 (ko)	2017-08-09
UA105384C2 (ru)	2014-05-12
CN102448493A (zh)	2012-05-09
AU2010232692C1 (en)	2017-06-01
RU2537142C2 (ru)	2014-12-27
SG174891A1 (en)	2011-11-28
EP2413967A1 (en)	2012-02-08
MA33248B1 (fr)	2012-05-02
KR20120005483A (ko)	2012-01-16
MX2011010273A (es)	2011-10-17
ZA201106076B (en)	2012-11-28
MX347978B (es)	2017-05-22
AR075998A1 (es)	2011-05-11
AU2010232692A1 (en)	2011-09-08
AU2010232692B2 (en)	2016-12-01
BRPI1011535A2 (pt)	2016-03-29
NZ595005A (en)	2014-04-30
JP5795306B2 (ja)	2015-10-14
TW201038284A (en)	2010-11-01

Publication	Publication Date	Title
IL217901A0 (en)	2012-03-29	Treatment of bdnf-related disorders using laquninimod
IL217824A0 (en)	2012-03-29	Treatment of of macrophage-related disorders
IL226401A0 (en)	2013-07-31	Methods for treating disorders related to @fgfBA
ZA201205829B (en)	2013-05-29	Treatment of respiratory disorders
ZA201106076B (en)	2012-11-28	Treatment of insulin-resistant disorders
HK1166472A1 (zh)	2012-11-02	運動障礙相關病症的治療
GB0915515D0 (en)	2009-10-07	Treatment of vasculoproliferative conditions
GB0919097D0 (en)	2009-12-16	Treatment of hard surfaces
ZA201107449B (en)	2012-06-27	Compounds for the treatment of metabolic disorders
ZA201107446B (en)	2012-06-27	Compounds for the treatment of metabolic disorders
IL206491A0 (en)	2010-12-30	Treatment of produce
GB0904284D0 (en)	2009-04-22	Compounds for the treatment of metabolic disorders
IL225896A0 (en)	2013-06-27	Treatment of mecp-2 related disorders
WO2010099044A9 (en)	2010-12-16	Treatment of immunosuppression-related disorders
GB0901456D0 (en)	2009-03-11	Treatment of psoriasis
EP2473171A4 (en)	2012-07-11	METHODS OF TREATING MITOCHONDRIAL DISORDERS USING METALLOPORPHYRINS
GB0809476D0 (en)	2008-07-02	Treatment of neurodegenerative disorders
EP2638038A4 (en)	2014-03-12	METHOD OF TREATING MENTAL DISORDERS
IL200753A0 (en)	2010-06-30	Treatment of psoriasis
IL223385B (en)	2020-06-30	Treatment of inflammatory disorders
IL210558A0 (en)	2011-03-31	Treatment of anxiety disorders
GB201003124D0 (en)	2010-04-14	Treatment of oxidative stress disorders
EP2440238A4 (en)	2013-01-16	Methods of Treatment
GB0819446D0 (en)	2008-12-03	Treatment of inflammatory disorders
GB0808623D0 (en)	2008-06-18	Treatment of keratinizing disorders